Metropolis Healthcare LtdNSE: METROPOLIS
Open the Metropolis Healthcare Ltd page
Follow Metropolis Healthcare LtdFree account. Get a note when Metropolis Healthcare Ltd files.
Q1 FY27 results analysis · August 04, 2026

Metropolis Healthcare Q1 FY27 Results Analysis: PAT Surges 26%, Cost Ratio Improves 113 bps

+25.8%PAT year on year, Rs. 56.67 Cr
Cofacto ResearchPublished August 04, 20262 min readPositive read
Quick summary

Metropolis Healthcare Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 450.21 Cr (+16.62% YoY) and PAT growth of +25.76% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 04, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 450.21 Cr (+16.62% YoY)
PAT (Q1)Rs. 56.67 Cr (+25.76% YoY)
EBITDA margin25.83% (+63 bps YoY)
EPS (Q1)Rs. 2.73 (+25.81% YoY)
Market capRs. 12,120.59 Cr
CMPRs. 584.50

Quarter Snapshot

Revenue grew 16.6% YoY and PAT grew 25.8%, with EBITDA margin of 25.8% within the company's target range. Cost management was excellent, led by a 113 bps improvement in cost of materials ratio. However, subsidiary contributions declined and no explicit full-year guidance was provided, limiting near-term catalysts.

Key Investment Insights

Key Positives

  • Revenue grew 16.62% YoY to Rs.450.21 crore
  • PAT (attributable to owners) grew 25.76% YoY to Rs.56.67 crore
  • EBITDA margin expanded 63 bps YoY to 25.83%, within the 25-26% target range
  • Cost of materials ratio improved 113 bps YoY to 19.35%
  • EBITDA grew 19.56% YoY, outpacing revenue growth and demonstrating operating leverage

Risk Factors

  • Other income fell 32.12% YoY to Rs.5.10 crore, reducing total income growth
  • Subsidiary contribution to PAT declined from Rs.9.70 crore in Q1FY26 to Rs.6.01 crore in Q1FY27, indicating thin margins at acquired entities
  • Finance costs rose 18.88% YoY to Rs.6.18 crore, tracking an expanded revenue base

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.